565456-75-9

Basic information

• Product Name: BOC-DL-CYCLOBUTYLALANINE
• Synonyms: BOC-DL-CYCLOBUTYLALANINE;Boc-3-Cyclobutylalanine;2-((tert-butoxycarbonyl)aMino)-3-cyclobutylpropanoic acid;N-Boc-RS-Cyclobutylalanine
• CAS NO: 565456-75-9
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.31
• Mol File: 565456-75-9.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: BOC-DL-CYCLOBUTYLALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-DL-CYCLOBUTYLALANINE(565456-75-9)
• EPA Substance Registry System: BOC-DL-CYCLOBUTYLALANINE(565456-75-9)

Safety Data

• Hazardous Substances Data: 565456-75-9(Hazardous Substances Data)

Usage

General Description

BOC-DL-CYCLOBUTYLALANINE is a chemical compound used in the synthesis and study of peptides and proteins. It is a derivative of the amino acid alanine, with a cyclobutyl group attached to the alpha carbon. The BOC (tert-butyloxycarbonyl) group is a protective group commonly used in peptide synthesis to prevent unwanted side reactions. BOC-DL-CYCLOBUTYLALANINE is used as a building block in the creation of peptides with specific structural and functional properties, and its synthesis and properties are of interest in the field of biochemistry and pharmaceutical research.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 394735-17-2 ethyl 2-amino-3-cyclobutylpropanoate 
• 17247-58-4 (Bromomethyl)cyclobutane 
• 1025799-39-6 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester 
• 816430-02-1 ethyl 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoate 

Downstream Products

• 394735-18-3 tert-butyl 3-cyclobutyl-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate 
• 394735-25-2 {(S)-2-[(1R,2S,5S)-2-(2-Carbamoyl-1-cyclobutylmethyl-2-hydroxy-ethylcarbamoyl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 
• 1036931-36-8 3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride 
• 394735-22-9 tert-butyl 4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-ylcarbamate 
• 394730-60-0 boceprevir 
• 394735-20-7 (2-cyano-1-cyclobutylmethyl-2-hydroxyethyl)carbamic acid tert-butyl ester 
• 394735-19-4 (2-cyclobutyl-1-formylethyl)carbamic acid tert-butyl ester 

Relevant articles and documents

PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF

THE PRESENT INVENTION RELATES TO AN IMPROVED PROCESS FOR THE PREPARATION OF (1R,5S)-N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL]-3-[2(S)-[[[(1,1-DIMETHYLETHYL)AMINO]CARBONYL] AMINO]-3,3-DIMETHYL-1-OXOBUTYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXAN-2(S)-CARBOXAMIDE AND ITS INTERMEDIATES

Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor

Compositions and therapeutic combinations are provided including at least one compound selected from the group consisting of compounds of Formulae I to XXVI as defined herein as well as methods of treatment, prevention or amelioration of one or more symptoms of hepatitis C, treating disorders associated with HCV virus, modulating activity of HCV protease, in which liver to plasma concentration ratio of the compound ranges from about 2:1 to about 10:1.

Methods of treating hepatitis C virus

Methods for preventing, ameliorating or treating one or more symptoms of Hepatitis C virus (HCV), modulating HCV protease activity and/or inhibiting cathepsin activity in a subject, wherein the methods comprise administering to a subject in need of such treatment a dosage formulation containing at least one compound of Formulae I-XXVI herein, wherein the dosage formulation is capable of maintaining an average Cmin plasma concentration of the compound at or above 10 ng/ml.